Rep. Neal Dunn continues pushing to disclose all review documents to sponsors after they receive a complete response letter even though industry officials, in addition to the US Food and Drug Administration, do not seem overly supportive.
Representatives of the Pharmaceutical Research and Manufacturers of America and Biotechnology Innovation Organization, two influential trade groups, chose to focus instead on communication during the application assessment when Dunn raised